International law firm Bird & Bird advised BrainEver, a French biotech company specialised in the development of new therapies for patients with age-related neurodegenerative diseases, on its €33 million Series B fundraising round to fight Charcot's disease.
Critical Path Ventures and the European Innovation Council (EIC) led this new financing round, in which existing investors Ibionext and Relyens also participated.
With this new funding, the French biotech company, co-founded in 2015 by Bernard Gilly, CEO, and Professor Alain Prochiantz, Scientific Director (Collège de France), aims to launch a Phase I/II clinical trial by the end of 2025 for its innovative treatment targeting amyotrophic lateral sclerosis (ALS), more commonly known as Charcot's disease.
Bird & Bird advised BrainEver on this transaction with a team composed of
Emmanuelle Porte, partner and
Elodie Vardon, associate.
EIC was assisted by Bignon Lebray, with a team comprising Alexandre Ghesquière, partner, and Martin Wartelle, associate, and Critical Path Ventures was assisted by AGN Avocats, with a team comprising Emel Ozdemir and Antonin Cubertafond, partners.
